Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
6
×
genentech
6
×
life sciences
national blog main
national top stories
roche
6
×
boston blog main
boston top stories
san francisco blog main
san francisco top stories
cancer
boston
deals
eli lilly
fda
indiana blog main
indiana top stories
national
new york blog main
new york top stories
novartis
avapritinib
biogen
blueprint medicines
boulder/denver blog main
boulder/denver top stories
cancer immunotherapy
celgene
clinical trials
detroit blog main
detroit top stories
drug prices
europe top stories
investing
medullary thyroid cancer
non-small cell lung cancer
pfizer
pralsetinib
raleigh-durham blog main
raleigh-durham top stories
What
drug
cancer
fda
roche
approval
blueprint
latest
medicine
medicines
ret
therapy
acquire
address
agreed
alzheimer’s
annual
approved
approves
atrophy
big
billion
bio
breast
broad
cancer's
candidate
carries
certain
clinical
companies
conference
confidence
currently
daily
data
designed
didn’t
different
esmo
european
Language
unset
Current search:
genentech
×
biotech
×
roche
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine